Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Lee Jackson | Jan 6, 2017 at 8:35 AM EST

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of…

Chris Lange | Jan 5, 2017 at 11:40 AM EST

Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday

As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a…

Chris Lange | Jan 5, 2017 at 11:05 AM EST

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

Major Dow Jones Industrial Average companies in the health care sector saw a relatively strong 2016, with most posting a…

Chris Lange | Jan 4, 2017 at 12:15 PM EST

Wednesday’s Top 5 Biopharma Movers

A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving…

Chris Lange | Jan 3, 2017 at 11:35 AM EST

Braeburn Pharmaceuticals Gears Up for IPO

Braeburn Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Jan 3, 2017 at 11:10 AM EST

Tuesday’s Biggest Biotech and Pharma Moves

To kick off the New Year, Clovis Oncology a few other biotech companies made massive runs on this first day…

Chris Lange | Jan 3, 2017 at 10:35 AM EST

Jounce Therapeutics Files for IPO

Jounce Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Chris Lange | Jan 3, 2017 at 10:20 AM EST

Is This the Implosion of Inotek?

Inotek Pharmaceuticals saw its shares get more than halved early on Tuesday after the company provided an update on its…

Trey Thoelcke | Dec 30, 2016 at 11:15 AM EST

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.

Jon C. Ogg | Dec 30, 2016 at 10:45 AM EST

Will 2017 Be a Make or Break Year for FibroGen?

FibroGen could be a very important stock in its sector in 2017, with its data from multiple studies coming out…

Chris Lange | Dec 30, 2016 at 7:45 AM EST

7 Key FDA Decisions and Catalysts Expected in January and February

24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two…

Chris Lange | Dec 29, 2016 at 11:55 AM EST

EndoLogix Recovers Slightly After Resuming Shipments

Endologix shares dropped sharply on news of a temporary hold on the shipments of its abdominal aortic aneurysms products, but…

Chris Lange | Dec 29, 2016 at 11:05 AM EST

Cempra Shares Get Halved After Receipt of CRL From the FDA

Shares of Cempra were halved on Thursday after the company received a Complete Response Letter from the U.S. Food and…

Chris Lange | Dec 28, 2016 at 3:43 PM EST

Galena Rises on FDA Approval

Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA)…

Chris Lange | Dec 28, 2016 at 10:25 AM EST

Short Interest Rises in Major Pharma

The December 15 short interest data have been compared with the previous figures, and short interest increased in most of…

1 … 178 179 180 181 182 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

Wednesday’s Top 5 Biopharma Movers

Braeburn Pharmaceuticals Gears Up for IPO

Tuesday’s Biggest Biotech and Pharma Moves

Jounce Therapeutics Files for IPO

Is This the Implosion of Inotek?

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Will 2017 Be a Make or Break Year for FibroGen?

7 Key FDA Decisions and Catalysts Expected in January and February

EndoLogix Recovers Slightly After Resuming Shipments

Cempra Shares Get Halved After Receipt of CRL From the FDA

Galena Rises on FDA Approval

Short Interest Rises in Major Pharma

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that's now reaching retirees' statements

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Health and Healthcare Articles

All Health and Healthcare Articles

These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday

2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth

Wednesday’s Top 5 Biopharma Movers

Braeburn Pharmaceuticals Gears Up for IPO

Tuesday’s Biggest Biotech and Pharma Moves

Jounce Therapeutics Files for IPO

Is This the Implosion of Inotek?

3 Sleeper Biotechs That Could Bounce Back Strong in 2017

Will 2017 Be a Make or Break Year for FibroGen?

7 Key FDA Decisions and Catalysts Expected in January and February

EndoLogix Recovers Slightly After Resuming Shipments

Cempra Shares Get Halved After Receipt of CRL From the FDA

Galena Rises on FDA Approval

Short Interest Rises in Major Pharma

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that’s now reaching retirees’ statements

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Featured Reads

The DOJ just charged 324 defendants in the largest Medicare fraud takedown ever — $14.6 billion that's now reaching retirees' statements

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check